A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective
dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid
arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha
(TNFa) antagonist due to lack of efficacy.